Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
ATFB
MCID: FML001
MIFTS: 65

Familial Atrial Fibrillation (ATFB)

Categories: Blood diseases, Cardiovascular diseases, Genetic diseases, Mental diseases, Rare diseases, Respiratory diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Familial Atrial Fibrillation

About this section

MalaCards integrated aliases for Familial Atrial Fibrillation:

Name: Familial Atrial Fibrillation 12 20 43 58 29 6 15 70
Atrial Fibrillation, Familial 20 43 54
Atfb 12 20
Atrial Fibrillation Autosomal Dominant 20
Autosomal Dominant Atrial Fibrillation 20
Atrial Fibrillation, Familial, 1 70
Auricular Fibrillation 43
Atrial Fibrillation 70

Characteristics:

Orphanet epidemiological data:

58
familial atrial fibrillation
Inheritance: Autosomal dominant;

Classifications:

MalaCards categories:
Global: Rare diseases Genetic diseases
Anatomical: Cardiovascular diseases Respiratory diseases Blood diseases Mental diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:0050650
ICD10 via Orphanet 33 I48.9
Orphanet 58 ORPHA334
UMLS 70 C0004238 C1843687 C3468561
Sources

Summaries for Familial Atrial Fibrillation

About this section
GARD : 20 Familial atrial fibrillation is an inherited heart condition that disrupts the heart's rhythm. It is characterized by erratic electrical activity in the heart's upper chambers (the atria), causing an irregular response in the heart's lower chambers (the ventricles). This causes a fast and irregular heartbeat ( arrhythmia ). Signs and symptoms may include dizziness, chest pain, palpitations, shortness of breath, or fainting. Affected people also have an increased risk of stroke and sudden death. While complications may occur at any age, some affected people never have associated health problems. Familial atrial fibrillation may be caused by changes ( mutations ) in any of various genes, some of which have not been identified. It is most often inherited in an autosomal dominant manner, but autosomal recessive inheritance has been reported.

MalaCards based summary : Familial Atrial Fibrillation, also known as atrial fibrillation, familial, is related to atrial fibrillation and cardiac arrhythmia, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Familial Atrial Fibrillation is MYL4 (Myosin Light Chain 4), and among its related pathways/superpathways are Cardiac conduction and cGMP-PKG signaling pathway. The drugs Ranolazine and Hydroxychloroquine have been mentioned in the context of this disorder. Affiliated tissues include heart, endothelial and lung, and related phenotypes are cardiovascular system and homeostasis/metabolism

Disease Ontology : 12 An atrial fibrillation that has material basis in autosomal dominant inheritance of the familial atrial fibrillation (ATFB) genes.

MedlinePlus Genetics : 43 Familial atrial fibrillation is an inherited abnormality of the heart's normal rhythm. Atrial fibrillation is characterized by episodes of uncoordinated electrical activity (fibrillation) in the heart's upper chambers (the atria), which cause a fast and irregular heartbeat. If untreated, this abnormal heart rhythm (arrhythmia) can lead to dizziness, chest pain, a sensation of fluttering or pounding in the chest (palpitations), shortness of breath, or fainting (syncope). Atrial fibrillation also increases the risk of stroke and sudden death. Complications of atrial fibrillation can occur at any age, although some people with this heart condition never experience any health problems associated with the disorder.

Wikipedia : 73 Familial atrial fibrillation is an autosomal dominant heart condition that causes disruptions in the... more...

Sources

Related Diseases for Familial Atrial Fibrillation

About this section

Diseases in the Atrial Fibrillation family:

Atrial Fibrillation, Familial, 3 Atrial Fibrillation, Familial, 1
Atrial Fibrillation, Familial, 2 Atrial Fibrillation, Familial, 4
Atrial Fibrillation, Familial, 5 Atrial Fibrillation, Familial, 6
Atrial Fibrillation, Familial, 7 Atrial Fibrillation, Familial, 8
Atrial Fibrillation, Familial, 9 Atrial Fibrillation, Familial, 10
Atrial Fibrillation, Familial, 11 Atrial Fibrillation, Familial, 12
Atrial Fibrillation, Familial, 13 Atrial Fibrillation, Familial, 14
Atrial Fibrillation, Familial, 15 Atrial Fibrillation, Familial, 18
Familial Atrial Fibrillation

Diseases related to Familial Atrial Fibrillation via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 173)
# Related Disease Score Top Affiliating Genes
1 atrial fibrillation 31.9 SCN5A SCN4B SCN3B SCN2B PITX2 NUP155
2 cardiac arrhythmia 31.7 SCN5A SCN3B KCNQ1 KCNE2
3 long qt syndrome 31.4 SCN5A SCN4B SCN3B SCN2B KCNQ1 KCNJ2
4 ventricular fibrillation, paroxysmal familial, 1 31.2 SCN5A NKX2-5 KCNQ1 KCNE2
5 familial long qt syndrome 31.1 SCN5A SCN4B KCNQ1 KCNE2
6 sick sinus syndrome 31.1 SCN5A SCN3B NPPA GJA5
7 long qt syndrome 1 31.1 SCN5A SCN4B SCN3B SCN2B NKX2-5 KCNQ1
8 sinoatrial node disease 31.0 SCN5A SCN3B NKX2-5 KCNQ1 KCNJ2 GJA5
9 heart disease 31.0 SCN5A PITX2 NPPA NKX2-5 MYL4 KCNQ1
10 brugada syndrome 31.0 SCN5A SCN4B SCN3B SCN2B NUP155 NKX2-5
11 long qt syndrome 10 30.8 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2
12 long qt syndrome 6 30.8 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2
13 atrioventricular block 30.8 SCN5A NKX2-5 KCNQ1 KCNE2 GJA5 GATA4
14 short qt syndrome 30.8 SCN5A KCNQ1 KCNJ2 KCNE2
15 jervell and lange-nielsen syndrome 1 30.8 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2
16 syncope 30.8 SCN5A NPPA KCNQ1
17 dilated cardiomyopathy 30.7 SCN5A SCN4B SCN2B NPPA NKX2-5 KCNQ1
18 heart septal defect 30.7 PITX2 NPPA NKX2-5 GJA5 GATA6 GATA5
19 atrial fibrillation, familial, 1 30.7 PITX2 ATFB1
20 atrial heart septal defect 30.7 SCN5A PITX2 NPPA NKX2-5 GJA5 GATA6
21 progressive familial heart block, type ia 30.7 SCN5A GJA5
22 wolff-parkinson-white syndrome 30.6 SCN5A NKX2-5 KCNQ1
23 aortic valve disease 1 30.6 NKX2-5 KCNJ2 GATA6 GATA5 GATA4
24 patent ductus arteriosus 1 30.6 NKX2-5 GATA6 GATA4
25 atrial fibrillation, familial, 15 11.7
26 brugada syndrome 7 11.7
27 atrial fibrillation, familial, 11 11.2
28 atrial fibrillation, familial, 12 11.2
29 atrial fibrillation, familial, 13 11.2
30 atrial fibrillation, familial, 14 11.2
31 myasthenic syndrome, congenital, 5 10.6 SCN5A KCNQ1 KCNJ2 KCNE2 KCNA5 GJA5
32 long qt syndrome 13 10.6 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2
33 long qt syndrome 5 10.6 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2
34 long qt syndrome 9 10.6 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2
35 timothy syndrome 10.6 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2
36 andersen cardiodysrhythmic periodic paralysis 10.6 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2
37 long qt syndrome 11 10.6 SCN4B KCNQ1 KCNJ2 KCNE2
38 cardiac arrhythmia, ankyrin-b-related 10.6 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2
39 long qt syndrome 3 10.6 SCN5A SCN4B SCN3B KCNQ1 KCNJ2 KCNE2
40 long qt syndrome 12 10.6 SCN5A SCN4B KCNQ1 KCNE2
41 long qt syndrome 2 10.6 SCN5A SCN4B SCN3B KCNQ1 KCNJ2 KCNE2
42 catecholaminergic polymorphic ventricular tachycardia 10.6 SCN5A SCN4B SCN3B KCNQ1 KCNJ2 KCNE2
43 long qt syndrome 14 10.6 SCN5A KCNQ1 KCNJ2
44 mitral valve stenosis 10.6
45 intrinsic cardiomyopathy 10.6 SCN5A SCN4B NPPA NKX2-5 KCNQ1 KCNJ2
46 brugada syndrome 4 10.6 SCN5A KCNQ1 KCNJ2
47 congenital myasthenic syndrome 10.6 SCN5A NKX2-5 KCNQ1 KCNJ2 KCNE2 KCNA5
48 ventricular septal defect 10.6 NPPA NKX2-5 GATA6 GATA5 GATA4
49 progressive familial heart block 10.6 SCN5A NKX2-5 KCNQ1 GJA5
50 atrial standstill 10.6 SCN5A NPPA GJA5

Comorbidity relations with Familial Atrial Fibrillation via Phenotypic Disease Network (PDN): (show top 50) (show all 176)


Accessory Nerve Disease Acquired Polycythemia
Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Conjunctivitis Acute Cor Pulmonale
Acute Cystitis Acute Kidney Failure
Acute Myocardial Infarction Acute Vascular Insufficiency of Intestine
Alcohol Use Disorder Alcoholic Cardiomyopathy
Alcoholic Liver Cirrhosis Amyloidosis
Anemia, Autoimmune Hemolytic Anthracosis
Anxiety Aortic Aneurysm
Aortic Atherosclerosis Aortic Valve Disease 1
Aortic Valve Disease 2 Aortic Valve Insufficiency
Asbestosis Asthma
Atrial Tachyarrhythmia with Short Pr Interval Atrioventricular Block
Bacteremia 2 Basilar Artery Insufficiency
Benign Essential Hypertension Bleeding Disorder, Platelet-Type, 11
Blepharitis Bronchiectasis
Bronchitis Bronchopneumonia
Candidiasis Cardiac Arrest
Cardiac Arrhythmia Cardiogenic Shock
Cerebral Atherosclerosis Cerebral Degeneration
Cerebrovascular Disease Cholangitis
Cholecystitis Chronic Intestinal Vascular Insufficiency
Chronic Kidney Disease Chronic Pulmonary Heart Disease
Chronic Rheumatic Pericarditis Chronic Ulcer of Skin
Colorectal Cancer Conjunctivitis

Graphical network of the top 20 diseases related to Familial Atrial Fibrillation:



Diseases related to Familial Atrial Fibrillation
Sources

Symptoms & Phenotypes for Familial Atrial Fibrillation

About this section

UMLS symptoms related to Familial Atrial Fibrillation:


angina pectoris; chest pain; edema

MGI Mouse Phenotypes related to Familial Atrial Fibrillation:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.17 GATA4 GATA5 GATA6 GJA5 KCNA5 KCNJ2
2 homeostasis/metabolism MP:0005376 10 GATA4 GATA5 GATA6 GJA5 KCNA5 KCNE2
3 digestive/alimentary MP:0005381 9.86 GATA4 GATA5 GJA5 KCNE2 KCNJ2 KCNQ1
4 muscle MP:0005369 9.73 GATA4 GATA5 GATA6 GJA5 KCNA5 KCNJ2
5 respiratory system MP:0005388 9.17 GATA4 GATA6 GJA5 KCNJ2 NKX2-5 PITX2
Sources

Drugs & Therapeutics for Familial Atrial Fibrillation

About this section

Drugs for Familial Atrial Fibrillation (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 385)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ranolazine Approved, Investigational Phase 4 95635-55-5, 142387-99-3 56959
2
Hydroxychloroquine Approved Phase 4 118-42-3 3652
3
Canrenoic acid Approved, Withdrawn Phase 4 4138-96-9
4
carbamide peroxide Approved Phase 4 124-43-6
5
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
6
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
7
Antazoline Approved Phase 4 91-75-8 2200
8
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
9
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
10
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
11
fluindione Approved, Investigational Phase 4 957-56-2
12
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
13
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
14
Terazosin Approved Phase 4 63590-64-7 5401
15
Quinidine Approved, Investigational Phase 4 56-54-2 441074
16
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
17
Nifedipine Approved Phase 4 21829-25-4 4485
18
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
19
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
20
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
21
Acetaminophen Approved Phase 4 103-90-2 1983
22
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
23
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
24
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
25
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
26
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
27
Ezetimibe Approved Phase 4 163222-33-1 150311
28
Pantoprazole Approved Phase 4 102625-70-7 4679
29
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
30
Phenylpropanolamine Approved, Vet_approved, Withdrawn Phase 4 14838-15-4 26934
31
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
32
Amlodipine Approved Phase 4 88150-42-9 2162
33
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
34
Ticlopidine Approved Phase 4 55142-85-3 5472
35
Atorvastatin Approved Phase 4 134523-00-5 60823
36
Liraglutide Approved Phase 4 204656-20-2 44147092
37
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
38
Methohexital Approved Phase 4 151-83-7 9034
39
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
40
Ketoconazole Approved, Investigational Phase 4 65277-42-1 47576
41
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560
42
tannic acid Approved Phase 4 1401-55-4
43
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
44
Metoprolol Approved, Investigational Phase 4 51384-51-1, 37350-58-6 4171
45
Enoxaparin Approved Phase 4 9005-49-6 772
46
Ticagrelor Approved Phase 4 274693-27-5 9871419
47
Verapamil Approved Phase 4 52-53-9 2520
48
Procainamide Approved Phase 4 51-06-9 4913
49
Diltiazem Approved, Investigational Phase 4 42399-41-7 39186
50
Digoxin Approved Phase 4 20830-75-5 30322 2724385

Interventional clinical trials:

(show top 50) (show all 2568)
# Name Status NCT ID Phase Drugs
1 Randomized Controlled Trial to Evaluate Implanted Event Recorders for the First Diagnosis of Atrial Fibrillation in High-risk Patients Unknown status NCT01461434 Phase 4
2 PV-Isolation for Paroxysmal Atrial Fibrillation: Isolation of the Arrhythmogenic Vein(s) vs. Isolation of All Veins Unknown status NCT00605748 Phase 4
3 Safety and Efficacy of Transvenous Pulmonary Isolation for the Treatment of Atrial Fibrillation: A Prospective Randomized Study Comparing Radiofrequency Energy With Cryoenergy Unknown status NCT00773539 Phase 4
4 Atrial Fibrillation Ablation Compared to Rate Control Strategy in Patients With Recently Diagnosed Impaired Left Ventricular Function: a Multicenter, Randomized Controlled Trial Unknown status NCT02509754 Phase 4
5 Test of Efficacy and Safety of the Dual Antiplatelet Therapy Compared to the Combination of Oral Anticoagulant Therapy + Dual Antiplatelet Therapy in Patients With Atrial Fibrillation With Low-moderate Risk Submitted to Coronary Stent Implantation Unknown status NCT01141153 Phase 4 Acetylsalicylic Acid + clopidogrel + acenocoumarol;Acetylsalicylic Acid + clopidogrel
6 Comparison of Efficacy and Safety Among DAbigatran, RIvaroxaban, and ApixabaN in Patients HavinG Non-Valvular Atrial Fibrillation in Taiwan (DARING-AF Study) Unknown status NCT02666157 Phase 4 Dabigatran etexilate;Rivaroxaban;Apixaban
7 Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients Unknown status NCT01610141 Phase 4
8 A Prospective Study of Medical Therapy Against Cryoballoon Ablation in Symptomatic Recent Onset Persistent Atrial Fibrilation Unknown status NCT02389218 Phase 4 sequential drug adjustment (propafenone, sotalol or flecainide)
9 Comparison of Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran in Patients With Non-valvular Atrial Fibrillation (RIVAL-AF Study) -Multicenter Randomized Study- Unknown status NCT02331602 Phase 4 Rivaroxaban;Dabigatran
10 SILENT - Subclinical AtrIal FibrilLation and StrokE PreveNtion Trial Unknown status NCT02004509 Phase 4 anticoagulant by physician criteria
11 The Early Diagnosis and Prevention of Ischemic Stroke and Cognition Decline Associated With Coronary Artery Disease Combined With Cerebral Artery Stenosis or Arrhythmia by 24-Hour Simultaneous Recorder of Electrocardiograph and Electroencephalography Unknown status NCT00247533 Phase 4
12 Randomized Study Comparing Cardioversion vs. Catheter Ablation in Patients With Persistent Atrial Fibrillation Unknown status NCT00196209 Phase 4
13 Improving Stroke Prevention in Atrial Fibrillation Through Pharmacist Prescribing: Program for the Identification of 'Actionable' AF (PIAAF) Rx Study Unknown status NCT03126214 Phase 4 Anticoagulants
14 Linear Anatomically Versus Focal Electrophysiologically Guided Substrate Ablation in Patients With Persistent Atrial Fibrillation Unknown status NCT00196157 Phase 4
15 Effect of Hydroxychloroquine on Atrial Fibrillation Recurrence After Radiofrequency Catheter Ablation in Patients With Atrial Fibrillation Unknown status NCT03592823 Phase 4 Hydroxychloroquine Sulfate 200 Mg Tablet
16 Atrial Fibrillation and Pericardial Drainage: Incidence of Postoperative Atrial Fibrillation According to the Type of Mediastinal Drainage Catheters Unknown status NCT02808897 Phase 4
17 Effects of Vernakalant and Flecainide on Atrial Contractility in Patients With Atrial Fibrillation Unknown status NCT01646281 Phase 4 Vernakalant;Flecainide
18 The Study of Rosuvastatin for Reduction of Postoperative Paroxysmal Atrial Fibrillation in Patient Undergoing Radiofrequency Catheter Ablation Unknown status NCT02502110 Phase 4 rosuvastatin
19 Impact of Colchicine Therapy on Arrhythmia Recurrence After Acute Pericardial Effusion Following Catheter Ablation of Atrial Fibrillation Unknown status NCT02260206 Phase 4 Colchicine
20 Left Atrial Ablation for Paroxysmal Atrial Fibrillation and Hypertension With Implantable Loop Recorder With or Without ROX Coupler Follow Up Study: The LAAPITUP 3 Study Unknown status NCT02243891 Phase 4
21 Comparison of a Rhythm Control Treatment Strategy Versus a Rate Control Strategy in Patients With Permanent or Long-term Persistent Atrial Fibrillation and Heart Failure Treated With Cardiac Resynchronization Therapy - a Pilot Study Unknown status NCT01850277 Phase 4 Amiodarone;Pharmacotherapy to slow and control ventricular rate
22 Comparison of Efficacy and Safety of Different Doses of Nifekalant Instant Cardioversion of Persistent Atrial Fibrillation During Radiofrequency Ablation：a Single-center Randomized Controlled Trial Unknown status NCT04209959 Phase 4 nifekalant
23 Clinical Efficacy of Potassium Canrenoate - Canrenone in Sinus Rhythm Restoration Among Patients With Atrial Fibrillation and Elevated Blood Pressure - a Pilot Randomized Controlled Trial. Unknown status NCT03536806 Phase 4 Saline 0.9%;Canrenone
24 A Randomized Study Comparing Dabigatran Etexilate Versus Warfarin in Chinese Patients With Nonvalvular Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention With Stenting (DES) Unknown status NCT03536611 Phase 4 dabigatran;warfarin
25 The Efficacy and Safety of Dabigatran Etexilate and Different Intensity Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation Unknown status NCT02646267 Phase 4 standard intensity warfarin;low intensity warfarin;dabigatran etexilate
26 Additional Linear Ablation Perpendicular to the Pulmonary Vein Isolation Line Reduces the Recurrence Rate of Paroxysmal Atrial Fibrillation (ALA-PAF) Unknown status NCT02637453 Phase 4
27 A Prospective, Multi-Center, Pilot Study to Compare the Safety and Effectiveness of WATCHMAN Left Atrial Appendage Occlusion Device With Rivaroxaban for Stroke Prevention in Patients With Atrial Fibrillation Unknown status NCT02549963 Phase 4 Rivaroxaban
28 Dronedarone in Pacemaker Patients With Paroxysmal Atrial Fibrillation Unknown status NCT01070667 Phase 4 Dronedarone;Placebo
29 Impact of Irbesartan on Oxidative Stress and C-Reactive Protein Levels in Patients With Persistent Atrial Fibrillation Unknown status NCT00613496 Phase 4 irbesartan;placebo
30 A Nationwide Multicenter Trial Assessing the Effects of Catheter Ablation on Burden of Atrial Fibrillation Recorded by Implantable Cardiac Monitor Unknown status NCT02639793 Phase 4
31 Phenprocoumon Versus Dabigatran in Subjects With Atrial Fibrillation and Left Atrial Thrombus - a Prospective, Randomized, Controlled, Open-label One Year Follow-up Pilot Study Unknown status NCT02591225 Phase 4 Dabigatranetexilate;Phenprocoumon
32 Catheter Ablation for Atrial Fibrillation: A Multicenter Clinical Trial Unknown status NCT01113294 Phase 4
33 Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer: A Controlled, Randomized, Double Blinded Trial Unknown status NCT00724581 Phase 4 Amiodarone
34 Low Dose of Diltiazem for Rate Control of Atrial Fibrillation Unknown status NCT00834925 Phase 4 low dose diltiazem
35 Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study (AFIRE Study) Unknown status NCT02642419 Phase 4 Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel);Rivaroxaban
36 Pulmonary Vein Isolation With Versus Without Continued Antiarrhythmic Drug Treatment in Subjects With Recurrent Atrial Fibrillation: A Prospective 2-Centre Randomized Controlled Clinical Study (POWDER-AF) Unknown status NCT02475642 Phase 4
37 Rivaroxaban Once Daily Versus Dose-adjusted Vitamin K Antagonist on the Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF) Unknown status NCT03490994 Phase 4 Rivaroxaban;Warfarin + LMWH
38 N-3 Fatty Acids for the Prevention of Atrial Fibrillation in Patients With Acute Heart Failure Unknown status NCT00692718 Phase 4 Epadel, Eicosapentaenoic acid
39 Improved Exercise Tolerance in Participants With PReserved Ejection Fraction by Spironolactone on Myocardial Fibrosis in Atrial Fibrillation Unknown status NCT02673463 Phase 4 Spironolactone;Placebo
40 Atrial Fibrillation Therapy: A Multi-Center Clinical Study Unknown status NCT01341353 Phase 4 Digaoxin,amiodarone,β receptor antagonist, Calcium Antagonists
41 Rate Control in Atrial Fibrillation: A Randomized, Double-Blind, Crossover Comparison of Carvedilol and Metoprolol Tartrate Unknown status NCT02251509 Phase 4 Carvedilol;Metoprolol tartrate
42 Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention Unknown status NCT02334254 Phase 4 rivaroxaban and ticagrel therapy;triple antithrombotic regimen with warfarin, asipirin and clopidogrel
43 Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation Unknown status NCT02145546 Phase 4 Amiodarone;Propafenone;Sotalol
44 Intensive Statin Therapy Effect on Incidence of Post-Operative Atrial Fibrillation Unknown status NCT02029534 Phase 4 Atorvastatin 20 mg;Atorvastatin 80 mg
45 Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation Unknown status NCT00224341 Phase 4
46 Safety of Ticagrelor Plus Warfarin Versus Clopidogrel+Aspirin+Warfarin in Patients With Persistent or Permanent Atrial Fibrillation and Undergoing PCI-S: A Randomized, Open, Controlled, Parallel Group, Multi-center Trial Unknown status NCT02206815 Phase 4 Ticagrelor+Warfarin;Clopidogrel+Aspirin+Warfarin
47 Randomized Trial Comparing Diltiazem and Metoprolol For Atrial Fibrillation Rate Control Unknown status NCT02025465 Phase 4 Metoprolol;Diltiazem
48 A Randomized, Prospective Multicenter Pilot Study to Determine the Influence of the Ventricular Pacing Site on the Incidence of Atrial Fibrillation and Heart Failure in Patients With Indication for Permanent Pacemaker Stimulation Therapy. Unknown status NCT00292383 Phase 4
49 A Randomized, Prospective Multicenter Study to Determine the Incidence of Atrial Fibrillation and Heart Failure in Correlation to Stimulation Modes of Pacemakers Unknown status NCT00161551 Phase 4
50 The Use of Dabigatran Etexilate in Patients With Atrial Fibrillation After Mitral Valve Prosthetic Replacement Unknown status NCT03183843 Phase 4 Dabigatran Etexilate;Warfarin

Search NIH Clinical Center for Familial Atrial Fibrillation

Inferred drug relations via UMLS 70 / NDF-RT 51 :


anisindione
Atenolol
Deslanoside
Digitalis preparation
DIGITALIS,POWDERED
Digitoxin
Digoxin
Diltiazem
Diltiazem Hydrochloride
Diltiazem maleate
Disopyramide
Disopyramide Phosphate
DITIAZ
dofetilide
ibutilide
ibutilide fumarate
Metoprolol
metoprolol succinate
Metoprolol Tartrate
Procainamide
Procainamide Hydrochloride
Propafenone
Propafenone Hydrochloride
Quinidine
quinidine gluconate
quinidine polygalacturonate
Quinidine Sulfate
Sotalol
Sotalol Hydrochloride
Verapamil
Verapamil hydrochloride
Warfarin
Warfarin Sodium
WARFARIN SODIUM ISOPROPANOL COMPLEX
Sources

Genetic Tests for Familial Atrial Fibrillation

About this section

Genetic tests related to Familial Atrial Fibrillation:

# Genetic test Affiliating Genes
1 Familial Atrial Fibrillation 29
Sources

Anatomical Context for Familial Atrial Fibrillation

About this section

MalaCards organs/tissues related to Familial Atrial Fibrillation:

40
Heart, Endothelial, Lung, Brain, Spinal Cord, Bone, Kidney
Sources

Publications for Familial Atrial Fibrillation

About this section

Articles related to Familial Atrial Fibrillation:

(show top 50) (show all 109)
# Title Authors PMID Year
1
A mutation in the atrial-specific myosin light chain gene (MYL4) causes familial atrial fibrillation. 6 61
27066836 2016
2
A novel SCN5A gain-of-function mutation M1875T associated with familial atrial fibrillation. 61 54
18929244 2008
3
Cardiac sodium channel mutation in atrial fibrillation. 61 54
18088563 2008
4
Human KCNQ1 S140G mutation is associated with atrioventricular blocks. 54 61
17467630 2007
5
Atrial fibrillation in KCNE1-null mice. 54 61
15947250 2005
6
Identification of a KCNE2 gain-of-function mutation in patients with familial atrial fibrillation. 54 61
15368194 2004
7
KCNQ1 gain-of-function mutation in familial atrial fibrillation. 54 61
12522251 2003
8
Familial atrial rapid fibrillation associated with double mutations of SCN5A and KCNQ1. 61
33632346 2021
9
Connexin45 (GJC1) loss-of-function mutation contributes to familial atrial fibrillation and conduction disease. 61
33429106 2021
10
ISL1 loss-of-function variation causes familial atrial fibrillation. 61
32771629 2020
11
Clinical profile and outcome of familial versus non-familial atrial fibrillation. 61
32273045 2020
12
Generation of patient-specific induced pluripotent stem cells (ZZUSAHi001-A) derived from a familial atrial fibrillation patient carrying KCNA5 c.775G>A mutation. 61
32721895 2020
13
The Genetic Puzzle of Familial Atrial Fibrillation. 61
32118049 2020
14
Putative role of Brugada syndrome genes in familial atrial fibrillation. 61
31539150 2019
15
Electrophysiologic and molecular mechanisms of a frameshift NPPA mutation linked with familial atrial fibrillation. 61
31077706 2019
16
Characterization and haplotype study of 6 novel STR markers related to the KCNQ1 gene in heterogeneous cardiovascular disorders in the Iranian population 61
30866607 2019
17
A Novel PITX2c Gain-of-Function Mutation, p.Met207Val, in Patients With Familial Atrial Fibrillation. 61
30558760 2019
18
Proarrhythmia in the p.Met207Val PITX2c-Linked Familial Atrial Fibrillation-Insights From Modeling. 61
31695623 2019
19
Molecular Insights into the Short QT Syndrome. 61
31355049 2018
20
A SHOX2 loss-of-function mutation underlying familial atrial fibrillation. 61
30443179 2018
21
Familial clustering of atrial fibrillation and comparative longitudinal outcomes of familial and non-familial atrial fibrillation. 61
28485191 2017
22
Generation and cardiac subtype-specific differentiation of PITX2-deficient human iPS cell lines for exploring familial atrial fibrillation. 61
28677534 2017
23
A frameshift deletion in the sarcomere gene MYL4 causes early-onset familial atrial fibrillation. 61
27742809 2017
24
Outcomes Associated With Familial Versus Nonfamilial Atrial Fibrillation: A Matched Nationwide Cohort Study. 61
27866162 2016
25
Prognosis in Familial Atrial Fibrillation. 61
27866163 2016
26
A novel nonsense mutation in LMNA gene identified by Exome Sequencing in an atrial fibrillation family. 61
27373676 2016
27
Cardiac Delayed Rectifier Potassium Channels in Health and Disease. 61
27261823 2016
28
Clinical Features of Genetic Cardiac Diseases Related to Potassium Channelopathies. 61
27261827 2016
29
Examining rare and low-frequency genetic variants previously associated with lone or familial forms of atrial fibrillation in an electronic medical record system: a cautionary note. 61
25410959 2015
30
NKX2-6 mutation predisposes to familial atrial fibrillation. 61
25319568 2014
31
TNNI3K mutation in familial syndrome of conduction system disease, atrial tachyarrhythmia and dilated cardiomyopathy. 61
24925317 2014
32
Whole-exome sequencing in familial atrial fibrillation. 61
24727801 2014
33
KCNE2 modulates cardiac L-type Ca(2+) channel. 61
24681347 2014
34
Gremlin 2 promotes differentiation of embryonic stem cells to atrial fate by activation of the JNK signaling pathway. 61
24648383 2014
35
In silico investigation of a KCNQ1 mutation associated with familial atrial fibrillation. 61
24411289 2014
36
Pitx2, an atrial fibrillation predisposition gene, directly regulates ion transport and intercalated disc genes. 61
24395921 2014
37
A novel PITX2c loss-of-function mutation associated with familial atrial fibrillation. 61
24333117 2014
38
Selective targeting of gain-of-function KCNQ1 mutations predisposing to atrial fibrillation. 61
24006450 2013
39
Prevalence and spectrum of PITX2c mutations associated with familial atrial fibrillation. 61
23611745 2013
40
Characteristics of atrial fibrillation and comorbidities in familial atrial fibrillation. 61
23551519 2013
41
Mutations of the SCN4B-encoded sodium channel β4 subunit in familial atrial fibrillation. 61
23604097 2013
42
A KCNQ1 mutation causes a high penetrance for familial atrial fibrillation. 61
23350853 2013
43
A novel NKX2.5 loss-of-function mutation responsible for familial atrial fibrillation. 61
23525379 2013
44
A heterozygous variant in the human cardiac miR-133 gene, MIR133A2, alters miRNA duplex processing and strand abundance. 61
23497314 2013
45
Familial atrial fibrillation predicts increased risk of mortality: a study in Danish twins. 61
23255276 2013
46
[KCNQ1 mutation in patients with lone atrial fibrillation]. 61
23651960 2013
47
Polymorphisms but not mutations of the KCNQ1 gene are associated with lone atrial fibrillation in the Chinese Han population. 61
23710137 2013
48
Novel GATA5 loss-of-function mutations underlie familial atrial fibrillation. 61
23295592 2012
49
Novel GATA6 loss-of-function mutation responsible for familial atrial fibrillation. 61
22824924 2012
50
Chromosome 4q25 variants are genetic modifiers of rare ion channel mutations associated with familial atrial fibrillation. 61
22818067 2012
Sources

Variations for Familial Atrial Fibrillation

About this section

ClinVar genetic disease variations for Familial Atrial Fibrillation:

6 (show top 50) (show all 70)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 MYL4 NM_002476.2(MYL4):c.31G>A (p.Glu11Lys) SNV Pathogenic 224067 rs886037778 GRCh37: 17:45286819-45286819
GRCh38: 17:47209453-47209453
2 KCNQ1OT1 , KCNQ1 NM_181798.1(KCNQ1):c.1133+3G>A SNV Uncertain significance 304226 rs374767819 GRCh37: 11:2683314-2683314
GRCh38: 11:2662084-2662084
3 KCNQ1 NM_181798.1(KCNQ1):c.400-6G>T SNV Uncertain significance 304218 rs886048164 GRCh37: 11:2594070-2594070
GRCh38: 11:2572840-2572840
4 KCNJ2 NM_000891.2(KCNJ2):c.*2776del Deletion Uncertain significance 324885 rs886053343 GRCh37: 17:68175240-68175240
GRCh38: 17:70179099-70179099
5 KCNJ2 NM_000891.2(KCNJ2):c.*2774_*2775del Deletion Uncertain significance 324880 rs35656864 GRCh37: 17:68175206-68175207
GRCh38: 17:70179065-70179066
6 KCNJ2 NM_000891.2(KCNJ2):c.*1704_*1705dupCT Microsatellite Uncertain significance 324864 rs1555604187 GRCh37: 17:68174165-68174166
GRCh38: 17:70178024-70178025
7 KCNJ2 NM_000891.2(KCNJ2):c.*2775dup Duplication Uncertain significance 324879 rs35656864 GRCh37: 17:68175205-68175206
GRCh38: 17:70179064-70179065
8 KCNJ2 NM_000891.2(KCNJ2):c.-88C>T SNV Uncertain significance 324828 rs886053322 GRCh37: 17:68171093-68171093
GRCh38: 17:70174952-70174952
9 KCNJ2 NM_000891.2(KCNJ2):c.*1719_*1721dup Duplication Uncertain significance 324867 rs35753731 GRCh37: 17:68174168-68174169
GRCh38: 17:70178027-70178028
10 ABCC9 NM_005691.3(ABCC9):c.4316-14T>G SNV Uncertain significance 308032 rs886049168 GRCh37: 12:21960427-21960427
GRCh38: 12:21807493-21807493
11 KCNQ1-AS1 , KCNQ1 NM_181798.1(KCNQ1):c.1592C>A (p.Thr531Asn) SNV Uncertain significance 304230 rs377661455 GRCh37: 11:2869175-2869175
GRCh38: 11:2847945-2847945
12 GJA5 NM_181703.4(GJA5):c.*1211A>G SNV Uncertain significance 292438 rs886045244 GRCh37: 1:147229084-147229084
GRCh38: 1:147756951-147756951
13 KCNQ1-AS1 , KCNQ1 NM_181798.1(KCNQ1):c.*26C>A SNV Uncertain significance 304232 rs886048166 GRCh37: 11:2869259-2869259
GRCh38: 11:2848029-2848029
14 KCNQ1-AS1 , KCNQ1 NM_181798.1(KCNQ1):c.*887_*889del Deletion Uncertain significance 304264 rs886048175 GRCh37: 11:2870119-2870121
GRCh38: 11:2848889-2848891
15 KCNQ1-AS1 , KCNQ1 NM_181798.1(KCNQ1):c.1598C>A (p.Pro533His) SNV Uncertain significance 304231 rs886048165 GRCh37: 11:2869181-2869181
GRCh38: 11:2847951-2847951
16 KCNQ1-AS1 , KCNQ1 NM_181798.1(KCNQ1):c.*398C>T SNV Uncertain significance 304246 rs886048170 GRCh37: 11:2869631-2869631
GRCh38: 11:2848401-2848401
17 KCNQ1-AS1 , KCNQ1 NM_181798.1(KCNQ1):c.*160C>A SNV Uncertain significance 304234 rs886048167 GRCh37: 11:2869393-2869393
GRCh38: 11:2848163-2848163
18 KCNQ1-AS1 , KCNQ1 NM_181798.1(KCNQ1):c.*554T>G SNV Uncertain significance 304252 rs886048172 GRCh37: 11:2869787-2869787
GRCh38: 11:2848557-2848557
19 KCNQ1 NM_181798.1(KCNQ1):c.870+13C>T SNV Uncertain significance 304220 rs201364493 GRCh37: 11:2608935-2608935
GRCh38: 11:2587705-2587705
20 KCNJ2 NM_000891.2(KCNJ2):c.*1721dup Duplication Uncertain significance 324865 rs35753731 GRCh37: 17:68174168-68174169
GRCh38: 17:70178027-70178028
21 KCNQ1 NM_000218.2(KCNQ1):c.66C>T (p.Gly22=) SNV Uncertain significance 304215 rs886048162 GRCh37: 11:2466394-2466394
GRCh38: 11:2445164-2445164
22 KCNQ1 NM_181798.1(KCNQ1):c.269C>T (p.Ser90Phe) SNV Uncertain significance 304217 rs886048163 GRCh37: 11:2592600-2592600
GRCh38: 11:2571370-2571370
23 KCNJ2 NM_000891.2(KCNJ2):c.*324del Deletion Uncertain significance 324839 rs570173316 GRCh37: 17:68172786-68172786
GRCh38: 17:70176645-70176645
24 KCNJ2 NM_000891.2(KCNJ2):c.*3391_*3392dup Duplication Uncertain significance 324894 rs552636156 GRCh37: 17:68175852-68175853
GRCh38: 17:70179711-70179712
25 KCNJ2 NM_000891.2(KCNJ2):c.*2875_*2876del Deletion Uncertain significance 324887 rs561353262 GRCh37: 17:68175339-68175340
GRCh38: 17:70179198-70179199
26 KCNE2 NM_172201.1(KCNE2):c.-121C>T SNV Uncertain significance 339713 rs188625398 GRCh37: 21:35736342-35736342
GRCh38: 21:34364043-34364043
27 KCNJ2 NM_000891.2(KCNJ2):c.*2771_*2775del Deletion Uncertain significance 324882 rs35656864 GRCh37: 17:68175206-68175210
GRCh38: 17:70179065-70179069
28 KCNJ2 NM_000891.2(KCNJ2):c.*2772_*2775del Deletion Uncertain significance 324881 rs35656864 GRCh37: 17:68175206-68175209
GRCh38: 17:70179065-70179068
29 KCNJ2 NM_000891.2(KCNJ2):c.*1702dup Duplication Uncertain significance 324863 rs886053334 GRCh37: 17:68174165-68174166
GRCh38: 17:70178024-70178025
30 KCNJ2 NM_000891.2(KCNJ2):c.*1702_*1704dup Duplication Uncertain significance 324862 rs1555604193 GRCh37: 17:68174165-68174166
GRCh38: 17:70178024-70178025
31 KCNJ2 NM_000891.2(KCNJ2):c.*2770_*2775del Deletion Uncertain significance 324883 rs35656864 GRCh37: 17:68175206-68175211
GRCh38: 17:70179065-70179070
32 ABCC9 NM_005691.3(ABCC9):c.1165-7_1165-6del Deletion Uncertain significance 308043 rs35857705 GRCh37: 12:22063252-22063253
GRCh38: 12:21910318-21910319
33 KCNJ2 NM_000891.2(KCNJ2):c.-162delinsTCAGAGTAGT Indel Uncertain significance 324827 rs376713253 GRCh37: 17:68171019-68171019
GRCh38: 17:70174878-70174878
34 KCNQ1-AS1 , KCNQ1 NM_181798.1(KCNQ1):c.*292C>A SNV Uncertain significance 304240 rs886048169 GRCh37: 11:2869525-2869525
GRCh38: 11:2848295-2848295
35 KCNQ1 NM_000218.2(KCNQ1):c.29C>A (p.Ala10Asp) SNV Uncertain significance 304214 rs886048161 GRCh37: 11:2466357-2466357
GRCh38: 11:2445127-2445127
36 KCNJ2 NM_000891.2(KCNJ2):c.*1128dup Duplication Uncertain significance 324851 rs777658732 GRCh37: 17:68173591-68173592
GRCh38: 17:70177450-70177451
37 GJA5 NM_181703.4(GJA5):c.*1259C>T SNV Uncertain significance 292437 rs886045243 GRCh37: 1:147229036-147229036
GRCh38: 1:147756903-147756903
38 KCNJ2 NM_000891.2(KCNJ2):c.*1720_*1721dup Duplication Uncertain significance 324866 rs35753731 GRCh37: 17:68174168-68174169
GRCh38: 17:70178027-70178028
39 GJA5 NM_005266.6(GJA5):c.-67G>A SNV Uncertain significance 292457 rs36214923 GRCh37: 1:147245389-147245389
GRCh38: 1:147773285-147773285
40 KCNQ1-AS1 , KCNQ1 NM_181798.1(KCNQ1):c.*897G>T SNV Uncertain significance 304266 rs561861522 GRCh37: 11:2870130-2870130
GRCh38: 11:2848900-2848900
41 ABCC9 NM_005691.3(ABCC9):c.1165-4del Deletion Uncertain significance 308042 rs886049172 GRCh37: 12:22063250-22063250
GRCh38: 12:21910316-21910316
42 ABCC9 NM_005691.3(ABCC9):c.1165-19dup Duplication Uncertain significance 45385 rs35857705 GRCh37: 12:22063251-22063252
GRCh38: 12:21910317-21910318
43 KCNJ2 NM_000891.2(KCNJ2):c.1259C>T (p.Pro420Leu) SNV Uncertain significance 264482 rs749707062 GRCh37: 17:68172439-68172439
GRCh38: 17:70176298-70176298
44 KCNJ2 NM_000891.2(KCNJ2):c.*3463del Deletion Uncertain significance 324895 rs3841509 GRCh37: 17:68175918-68175918
GRCh38: 17:70179777-70179777
45 KCNQ1 NM_181798.1(KCNQ1):c.974G>A (p.Arg325Gln) SNV Uncertain significance 67030 rs145229963 GRCh37: 11:2610046-2610046
GRCh38: 11:2588816-2588816
46 KCNQ1 NM_181798.1(KCNQ1):c.808C>T (p.Arg270Trp) SNV Uncertain significance 52970 rs199472776 GRCh37: 11:2608860-2608860
GRCh38: 11:2587630-2587630
47 LAMA4 NM_001105206.3(LAMA4):c.3742A>G (p.Ile1248Val) SNV Uncertain significance 488160 rs547323858 GRCh37: 6:112454047-112454047
GRCh38: 6:112132845-112132845
48 ABCC9 NM_005691.3(ABCC9):c.2238-16del Deletion Uncertain significance 308036 rs886049170 GRCh37: 12:22016004-22016004
GRCh38: 12:21863070-21863070
49 KCNQ1OT1 , KCNQ1 NM_181798.1(KCNQ1):c.1012+21538C>T SNV Likely benign 304222 rs72850203 GRCh37: 11:2631622-2631622
GRCh38: 11:2610392-2610392
50 GJA5 NM_005266.6(GJA5):c.-152G= SNV Likely benign 368828 rs791286 GRCh37: 1:147245474-147245474
GRCh38: 1:147773370-147773370
Sources

Expression for Familial Atrial Fibrillation

About this section
Search GEO for disease gene expression data for Familial Atrial Fibrillation.
Sources

Pathways for Familial Atrial Fibrillation

About this section

Pathways related to Familial Atrial Fibrillation according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Cardiac conduction 65
Show member pathways